ABSTRACT
Epstein-Barr virus (EBV), a member of human herpesvirus, causes infectious mononucleosis, Burkitt’s lymphoma, nasopharyngeal carcinoma, gastric carcinoma and Hodgkin lymphomas. Epstein-Barr Nuclear Antigen 1, one of antigens encoded by EBV, comprises 641 amino acid residues. Among the latent infection Epstein-Barr Nuclear Antigen 1 acts in DNA replication, transcription of viral and cellular genes and in immortalisation of B lymphocytes. These special roles of Epstein-Barr Nuclear Antigen 1 make it an important drug target. Therefore, in this study, we create a ligand set of totally 2068 ligands to block binding DNA to Epstein-Barr Nuclear Antigen 1 antigen. After applying Lipinski’s Rule of Five filter to these ligands, 1637 ligands which are suitable to be a drug were run into molecular docking studies. It was seen that designed ligands show more activity to prevent binding DNA to Epstein-Barr Nuclear Antigen 1 antigen rather than ligands selected from the literature which are also studied in vitro and in silico.
Disclosure statement
No potential conflict of interest was reported by the authors.
ORCID
Selami Ercan http://orcid.org/0000-0002-9528-6122